Activist Investor Ananym Pushes Bio-Techne to Explore a Sale, Citing Years of Underperformance

Activist investor Ananym Capital Management sent a letter dated Monday to the board of Bio-Techne Corp. urging it to conduct a strategic review, according to Bloomberg News, which reviewed the letter. The review Ananym is calling for would explicitly include the possibility of selling the company to a larger industry player.

Bio-Techne is headquartered in Minneapolis and makes equipment for life-science research, diagnostics, and bioprocessing. As of Monday, its market capitalization stood at approximately $8.45 billion, according to Bloomberg, with shares down 8.2% so far in 2026.

What Ananym Is Arguing

Ananym's letter does not mince words. "While we are a new investor, shareholders have suffered for years as the company has continued to destroy value," the firm wrote, according to Bloomberg. "A failure to act now risks further value destruction and even permanent capital impairment, which the board has a duty to avoid by exploring all potential paths to preserving and enhancing value."

The firm acknowledged Bio-Techne has "unique, high-quality assets and strong customer relationships." The problem, Ananym argued, is execution. Organic growth has trailed peers, and investments in adjacent business areas have compressed operating margins without delivering corresponding revenue growth.

Ananym's case for a sale rests on sector dynamics. The life-science tools industry has been consolidating for several years, and larger players have paid substantial premiums for exactly the kind of assets Bio-Techne holds. A bigger acquirer, Ananym argued, could unlock cost, revenue, and platform synergies that Bio-Techne cannot access on its own.

The Case for Staying Independent

The strongest counter-argument is the one Bio-Techne's board could reasonably make: forced sales triggered by activist pressure rarely achieve the valuations a company would fetch if it ran its own process on its own timeline. Life-science tools multiples have compressed sector-wide since the post-pandemic peak, meaning any sale conducted under pressure in the current environment might not capture the full value of Bio-Techne's assets. A board focused on long-term shareholder value could argue that operational fixes, not a fire-sale review, are the right path. Bio-Techne did not respond to Bloomberg's request for comment as of publication, so the company's formal position is not yet on record.

Ananym's Track Record and Stake Size

Bloomberg's report does not disclose the size of Ananym's stake or the firm's prior campaign history. An activist with a 1% position has far less leverage than one sitting at 5% or above, and without knowing Ananym's holdings, the urgency of the board's obligation to respond is genuinely unclear. Ananym described itself as a "new investor" in the letter itself, which suggests the stake was built recently.

Sector Context

Bio-Techne is not an isolated case. The broader life-science tools sector has faced a difficult two-year stretch after the pandemic-era boom in research spending faded. Thermo Fisher Scientific, Danaher, and other large platforms have all dealt with slower end-market demand. Consolidation at the mid-cap level has picked up as smaller players struggle to sustain the R&D spending and commercial infrastructure that competing against those giants requires.

That consolidation wave is precisely Ananym's leverage. If larger buyers have already demonstrated willingness to pay up for comparable assets, Bio-Techne's board will have a harder time dismissing a strategic review outright without appearing to ignore a genuine value-creation path.

What Comes Next

Bio-Techne's board has no legal obligation to respond publicly to an activist letter, but ignoring it entirely carries reputational and shareholder-relations costs. The company's next scheduled earnings call is the most likely venue for management to address the pressure on record. Whether Ananym escalates, seeks board seats, or goes public with a broader proxy campaign will depend heavily on how Bio-Techne responds in the coming weeks. No regulatory filings disclosing Ananym's precise stake size had appeared in public records as of this report, according to Bloomberg, which means the full scope of the pressure the board faces remains an open question.